Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print      Mail a friend

Tuesday 01 May, 2018

BioPharma Credit PLC

Update on New Investment

RNS Number : 6476M
BioPharma Credit PLC
01 May 2018
 

1 May 2018

biopharma credit plc

update on new investment

 

 

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, would like to provide additional information on the investment which was initially disclosed on April 23, 2018.  BPCR is pleased to announce that today it closed and funded a senior-secured term loan to Sebela BT Holdings Inc., a subsidiary of Sebela Pharmaceuticals.  BPCR is the lead investor and collateral agent for the US$316 million loan and invested US$194 million alongside co-investors providing US$122 million.  Key terms of the financing include a five-year final maturity, a high single-digit floating coupon, and amortization beginning after the 3rd quarter of 2018.

 

Sebela Pharmaceuticals is a private specialty pharmaceutical company focused on gastro-intestinal (GI) medicines, dermatology, and women's health with pro-forma sales of approximately $250 million. Total leverage on Sebela is less than 4 times Debt to EBITDA. 

 

"We are pleased to be partnering with Sebela as they build a leading specialty pharmaceutical business", said Pedro Gonzalez de Cosio, Managing Member of Pharmakon Advisors.

 

-Ends-

 

Link Company Matters Limited

Company Secretary

 

 

Enquiries:

 

Buchanan

David Rydell/Mark Court/Jamie Hooper/Henry Wilson

+44 (0) 20 7466 5000

[email protected]

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27th March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

LEI: 213800AV55PYXAS7SY24

 

This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFVRSLIIVIT

a d v e r t i s e m e n t